Interleukin-6 antibody, dosed quarterly, cuts inflammatory markers in phase 2 studytranslating…

MUNICH — Treatment with the investigational interleukin-6 inhibitor pacibekitug was associated with large, sustained decreases in high-sensitivity C-reactive protein among adults with chronic kidney disease, according to phase 2 data.